Monomethyl auristatin E(CAS: 474645-27-7)

Monomethyl auristatin E (MMAE) is a peptide-based compound used in the development of targeted therapies for cancer. It combines the antitumor activity of auristatins with a linker to attach it to monoclonal antibodies or other drug carriers.

MMAE is primarily used in oncology as part of antibody-drug conjugates (ADCs). It targets cancer cells by attaching to monoclonal antibodies, delivering cytotoxic effects to malignant cells while minimizing damage to healthy tissues.

MMAE can be toxic and requires careful handling. It is generally safe when used under controlled conditions, following strict safety protocols. Protective measures include wearing appropriate personal protective equipment (PPE) and ensuring proper ventilation. Storage and disposal must comply with regulatory guidelines to minimize exposure risks.

MMAE should be stored in a cool, dark place away from direct sunlight and at a temperature between 2°C and 8°C. It should be kept in a tightly sealed container to prevent degradation. Avoid freezing and keep away from incompatible materials. Ensure the storage area has adequate ventilation to prevent the accumulation of flammable gases.